Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
COX2-selective and nonselective (ns) nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for chronic pain management. There are marked differences in the risk of adverse gastrointestinal (GI) and cardiovascular (CV) events among different NSAIDs. In 2017, publication of two randomized controlled trials and an individual patient-data meta-analysis provided robust data on the relative GI and CV tolerability profiles of currently available NSAIDs. The PRECISION study showed similar CV-event rates with celecoxib vs naproxen and ibuprofen, but GI tolerability was better for celecoxib. In the CONCERN study of high-GI-risk patients, celecoxib was associated with fewer adverse GI-tract events than naproxen. The meta-analysis showed no significant difference between celecoxib and ns-NSAIDs in the rate of acute myocardial infarction, and celecoxib was the only COX2-selective NSAID with a lower risk of adverse CV and GI events vs ns-NSAIDs. These data add to the body of knowledge about the relative tolerability of different NSAIDs and were used to propose an updated treatment algorithm. The decision about whether to use an NSAID and which one should be based on a patient's risk of developing adverse GI and CV events. Lower- and upper-GI-tract events need to be considered. Celecoxib has a better lower-GI-tract tolerability profile than ns-NSAIDs plus a proton-pump inhibitor. In addition, the latest data suggest that long-term use of celecoxib 200 mg/day may be appropriate for patients at increased CV risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 1×
“008).(34) Results from these studies led to the worldwide withdrawal of rofecoxib in 2004.”
ResultRisk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)
Berenbaum, F. (2013) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2012.11.012 · Cited by 1,718
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804 · cited 1×
“and for the shortest possible time to minimize the risk of CV events remains valid.(89)”
BackgroundIncreased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy
Lombardo, L., Foti, M., Ruggia, O., & Chiecchio, A. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.12.022 · Cited by 350
Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.5.ioi50013 · Cited by 329
Warner, T. D., & Mitchell, J. A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60137-3 · Cited by 166 · cited 1×
“However, COX2 selectivity varies among c2s-NSAIDs, being greater for lumiracoxib, rofecoxib, etoricoxib, and valdecoxib and comparatively lower for celecoxib.(37) In addition, other potential mechanisms might influence the CV risk of an NSAID.”
Background
Cited by
Shanthanna, H., Strand, N. H., Provenzano, D. A., Lobo, C. A., Eldabe, S., Bhatia, A., Wegener, J., Curtis, K., Cohen, S. P., & Narouze, S. (2020) · Anaesthesia · doi:10.1111/anae.15076 · Cited by 218
Nonnarcotic Methods of Pain Management
Finnerup, N. B. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1807061 · Cited by 153
Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations
Chang, Y., Zhu, M., Vannabouathong, C., Mundi, R., Chou, R. S., & Bhandari, M. (2021) · Pain Research and Management · doi:10.1155/2021/8857948 · Cited by 20
“Nonsteroidal anti-inflammatory drugs are also commonly used in the treatment of chronic pain [35, 36] but are associated with higher a risk of gastrointestinal events (risk ratio compared to placebo: 1.”
Background
Metadata
- Authors
- Ho, K. Y., Gwee, K. A., Cheng, Y. K., Yoon, K. H., Hee, H. T., & Omar, A. R.
- Venue
- Journal of Pain Research
- Publisher
- Informa UK Limited
- Published
- 2018-09
- Volume
- Volume 11
- Pages
- 1937-1948
- ISSN
- 1178-7090 (ISSN-L)
- OpenAlex
- W2890017731
- Cited by
- 110
- References
- 8
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.